Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a 'Buy' rating on Taysha Gene Therapies (NASDAQ:TSHA), but has lowered the price target from $13 to $7.
August 16, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity has maintained a 'Buy' rating on Taysha Gene Therapies, but lowered the price target from $13 to $7.
The news is directly related to Taysha Gene Therapies. While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term stock price. However, the impact is not necessarily negative as the 'Buy' rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100